27th Annual Conference of the International Society for Quality of Life Research
- PDF / 15,846,235 Bytes
- 196 Pages / 595.276 x 790.866 pts Page_size
- 104 Downloads / 251 Views
ABSTRACTS
27th Annual Conference of the International Society for Quality of Life Research
Springer Nature Switzerland AG 2020
Cutting Edge Research Plenary Session (1) Phase III randomized controlled trial of eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and advice)—An eHealth intervention during chemotherapy Galina Velikova, MD PhD FRCP, Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds Cancer Centre, Leeds, United Kingdom; Kate Absolom, Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds Cancer Centre, St James’s University Hospital, Leeds, United Kingdom; Lorraine Warrington, Leeds Institute of Medical Research at St James’s, University of Leeds Cancer Centre, St James’s University Hospital, Leeds, United Kingdom; Eleanor Hudson, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom; Jenny Hewison, Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom; Carolyn Morris, Patient representative, Independent Cancer Patients Voices, Brighton, United Kingdom; Patricia Holch, Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds Cancer Centre, St James’s University Hospital, Leeds, United Kingdom; Robert Carter, Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds Cancer Centre, St James’s University Hospital, Leeds, United Kingdom;Andrea Gibson, Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds Cancer Centre, St James’s University Hospital, Leeds, United Kingdom; Marie Holmes, Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds Cancer Centre, St James’s University Hospital, Leeds, United Kingdom; Zoe Rogers, Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds Cancer Centre, St James’s University Hospital, Leeds, United Kingdom; Lucy McParland, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom; Claire Hulme, University of Exeter, St Luke’s Campus, Exeter, United Kingdom; Julia Brown, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom Aims: eRAPID is an online eHealth system for patients to report symptoms during cancer treatment. It provides automated severitydependent advice to patients guiding self-management or medical
contact. Patient reports are transferred to the electronic patient records for immediate use in patient care. This trial evaluated the impact of eRAPID on symptom control, clinical care, patient self-efficacy, and quality of life (QOL). Methods: A prospective randomized parallel two-arm trial included colorectal, breast or gynecological patients commencing chemotherapy at a UK cancer center. Participants were randomized to usual care plus eRAPID or usual care (UC). eRAPID patients completed weekly symptom reports for 18 weeks. Primary outcome: symptom control at 18 weeks (Functional-AssessmentCancer-Therapy-Physical Wellbeing, FACT-PWB). Secondary outc
Data Loading...
